An Investigation of the Information Seeking Behavior of Medical Oncologists in Metropolitan Pittsburgh Using a Multimethod Approach

le Lomax, Edward C., Lowe, Henry J., Logan, Theodore F.
Foilsithe 1997

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

le Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.
Foilsithe in J Clin Oncol (2020)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

le Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Foilsithe in J Immunother Cancer (2018)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

le Clark, Joseph I, Curti, Brendan, Davis, Elizabeth J, Kaufman, Howard, Amin, Asim, Alva, Ajjai, Logan, Theodore F, Hauke, Ralph, Miletello, Gerald P, Vaishampayan, Ulka, Johnson, Douglas B, White, Richard L, Wiernik, Peter H, Dutcher, Janice P
Foilsithe in J Investig Med (2021)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

le Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Foilsithe in J Immunother Cancer (2017)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (procliv...

le Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Foilsithe in J Immunother Cancer (2014)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

le Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
Foilsithe 2012

NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept and High Dose Interleukin-2 (HD IL-2) or HD IL-2 Alone for Inoperable Stage III or IV Melanoma

le Tarhini, Ahmad A., Frankel, Paul, Ruel, Christopher, Ernstoff, Marc S., Kuzel, Timothy M., Logan, Theodore F., Khushalani, Nikhil I., Tawbi, Hussein A., Margolin, Kim A., Awasthi, Sanjay, Butterfield, Lisa H., McDermott, David, Chen, Alice, Lara, Primo N., Kirkwood, John M.
Foilsithe in Cancer (2018)

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

le Weber, Jeffrey S, Gibney, Geoff, Sullivan, Ryan J, Sosman, Jeffrey A, Slingluff, Craig L, Lawrence, Donald P, Logan, Theodore F, Schuchter, Lynn M, Nair, Suresh, Fecher, Leslie, Buchbinder, Elizabeth I, Berghorn, Elmer, Ruisi, Mary, Kong, George, Jiang, Joel, Horak, Christine, Hodi, F Stephen
Foilsithe in Lancet Oncol (2016)

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advance...

le Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M., Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F., Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J., Gansert, Jennifer, Andtbacka, Robert H.I., Kaufman, Howard L.
Foilsithe in J Clin Oncol (2018)

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

le Motzer, Robert J., Rini, Brian I., McDermott, David F., Redman, Bruce G., Kuzel, Timothy M., Harrison, Michael R., Vaishampayan, Ulka N., Drabkin, Harry A., George, Saby, Logan, Theodore F., Margolin, Kim A., Plimack, Elizabeth R., Lambert, Alexandre M., Waxman, Ian M., Hammers, Hans J.
Foilsithe in J Clin Oncol (2015)

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase...

le Amin, Asim, Dudek, Arkadiusz Z, Logan, Theodore F, Lance, Raymond S, Holzbeierlein, Jeffrey M, Knox, Jennifer J, Master, Viraj A, Pal, Sumanta K, Miller, Wilson H, Karsh, Lawrence I, Tcherepanova, Irina Y, DeBenedette, Mark A, Williams, W Lee, Plessinger, Douglas C, Nicolette, Charles A, Figlin, Robert A
Foilsithe in J Immunother Cancer (2015)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in advanced clear cell renal cell carcinoma

le Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.
Foilsithe in Cancer (2019)

Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

le Armstrong, Andrew J, Halabi, Susan, Eisen, Tim, Broderick, Samuel, Stadler, Walter M, Jones, Robert J, Garcia, Jorge A, Vaishampayan, Ulka N, Picus, Joel, Hawkins, Robert E, Hainsworth, John D, Kollmannsberger, Christian K, Logan, Theodore F, Puzanov, Igor, Pickering, Lisa M, Ryan, Christopher W, Protheroe, Andrew, Lusk, Christine M, Oberg, Sadie, George, Daniel J
Foilsithe in Lancet Oncol (2016)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

le Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Foilsithe in Cancer Immunol Immunother (2016)

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

le Choueiri, Toni K., Vaishampayan, Ulka, Rosenberg, Jonathan E., Logan, Theodore F., Harzstark, Andrea L., Bukowski, Ronald M., Rini, Brian I., Srinivas, Sandy, Stein, Mark N., Adams, Laurel M., Ottesen, Lone H., Laubscher, Kevin H., Sherman, Laurie, McDermott, David F., Haas, Naomi B., Flaherty, Keith T., Ross, Robert, Eisenberg, Peter, Meltzer, Paul S., Merino, Maria J., Bottaro, Donald P., Linehan, W. Marston, Srinivasan, Ramaprasad
Foilsithe 2013

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma

le McDermott, David F., Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A., Clark, Joseph I., Sosman, Jeffrey A., Dutcher, Janice P., Logan, Theodore F., Curti, Brendan D., Ernstoff, Marc S., Appleman, Leonard, Wong, Michael K.K., Khushalani, Nikhil I., Oleksowicz, Leslie, Vaishampayan, Ulka N., Mier, James W., Panka, David J., Bhatt, Rupal S., Bailey, Alexandra S., Leibovich, Bradley C., Kwon, Eugene D., Kabbinavar, Fairooz F., Belldegrun, Arie S., Figlin, Robert A., Pantuck, Allan J., Regan, Meredith M., Atkins, Michael B.
Foilsithe in Clin Cancer Res (2014)